Literature DB >> 15567150

Deficiency of inducible nitric oxide synthase exacerbates hepatic fibrosis in mice fed high-fat diet.

Yi Chen1, Shigenari Hozawa, Sadaaki Sawamura, Shinkichi Sato, Naoto Fukuyama, Chizuko Tsuji, Tetsuya Mine, Yasunori Okada, Ryuzaburo Tanino, Yoichi Ogushi, Hiroe Nakazawa.   

Abstract

The role of inducible nitric oxide synthase (iNOS) in the progression of fibrosis during nonalcoholic steatohepatitis remains to be elucidated. This study examined the role of iNOS in the progression of fibrosis during steatohepatitis by comparing iNOS knockout (iNOS(-/-)) and wild-type (iNOS(+/+)) mice that were fed a high-fat diet. Severe fatty metamorphosis developed in the liver of iNOS(+/+) and iNOS(-/-) mice. Fibrotic changes were marked in iNOS(-/-) mice. Gelatin zymography showed that pro MMP-2 and pro MMP-9 protein expressions were more highly induced in iNOS(+/+) mice than in iNOS(-/-) mice. Active forms of MMP-2 and MMP-9 were clearly present only in the liver tissue of iNOS(+/+) mice. In situ zymography showed strong gelatinolytic activities in the liver tissue of iNOS(+/+) mice, but only spotty activity in iNOS(-/-)mice. iNOS may attenuate the progression of liver fibrosis in steatohepatitis, in part by inducing MMP-2 and MMP-9 expression and augmenting their activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15567150     DOI: 10.1016/j.bbrc.2004.10.202

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Adiponectin attenuates liver fibrosis by inducing nitric oxide production of hepatic stellate cells.

Authors:  Zhixia Dong; Lin Su; Saeed Esmaili; Tristan J Iseli; Mehdi Ramezani-Moghadam; Liangshuo Hu; Aimin Xu; Jacob George; Jianhua Wang
Journal:  J Mol Med (Berl)       Date:  2015-07-09       Impact factor: 4.599

Review 2.  Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy.

Authors:  Nestor F Gonzalez-Cadavid; Jacob Rajfer
Journal:  Nat Rev Urol       Date:  2010-03-09       Impact factor: 14.432

3.  The NOX1 isoform of NADPH oxidase is involved in dysfunction of liver sinusoids in nonalcoholic fatty liver disease.

Authors:  Misaki Matsumoto; Jia Zhang; Xueqing Zhang; Junjie Liu; Joy X Jiang; Kanji Yamaguchi; Akiyuki Taruno; Masato Katsuyama; Kazumi Iwata; Masakazu Ibi; Wenhao Cui; Kuniharu Matsuno; Yoshinori Marunaka; Yoshito Itoh; Natalie J Torok; Chihiro Yabe-Nishimura
Journal:  Free Radic Biol Med       Date:  2017-12-20       Impact factor: 7.376

Review 4.  Genetically modified mouse models for the study of nonalcoholic fatty liver disease.

Authors:  Perumal Nagarajan; M Jerald Mahesh Kumar; Ramasamy Venkatesan; Subeer S Majundar; Ramesh C Juyal
Journal:  World J Gastroenterol       Date:  2012-03-21       Impact factor: 5.742

5.  The role of iNOS in cholesterol-induced liver fibrosis.

Authors:  Sarit Anavi; Michal Eisenberg-Bord; Michal Hahn-Obercyger; Olga Genin; Mark Pines; Oren Tirosh
Journal:  Lab Invest       Date:  2015-06-22       Impact factor: 5.662

6.  Hydrolyzed whey peptide-based diet ameliorates hepatic ischemia-reperfusion injury in the rat nonalcoholic fatty liver.

Authors:  Akira Nii; Tohru Utsunomiya; Mitsuo Shimada; Toru Ikegami; Hiroki Ishibashi; Satoru Imura; Yuji Morine; Tetsuya Ikemoto; Hajime Sasaki; Akihiro Kawashima
Journal:  Surg Today       Date:  2014-02-04       Impact factor: 2.549

7.  Nitric oxide participation in granulomatous response induced by Paracoccidioides brasiliensis infection in mice.

Authors:  Angela Satie Nishikaku; Raphael Fagnani Sanchez Molina; Luciana Cristina Ribeiro; Renata Scavone; Bernardo Paulo Albe; Cláudia Silva Cunha; Eva Burger
Journal:  Med Microbiol Immunol       Date:  2009-04-10       Impact factor: 3.402

8.  Serum asymmetric dimethylarginine levels are independently associated with procollagen III N-terminal peptide in nonalcoholic fatty liver disease patients.

Authors:  Hideyuki Hyogo; Sho-Ichi Yamagishi; Sayaka Maeda; Kei Fukami; Seiji Ueda; Seiya Okuda; Takashi Nakahara; Yuki Kimura; Tomokazu Ishitobi; Kazuaki Chayama
Journal:  Clin Exp Med       Date:  2012-11-23       Impact factor: 3.984

9.  Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats.

Authors:  Koji Fujita; Masato Yoneda; Koichiro Wada; Hironori Mawatari; Hirokazu Takahashi; Hiroyuki Kirikoshi; Masahiko Inamori; Yuichi Nozaki; Shiro Maeyama; Satoru Saito; Tomoyuki Iwasaki; Yasuo Terauchi; Atsushi Nakajima
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

10.  Lipopolysaccharide Reverses Hepatic Stellate Cell Activation Through Modulation of cMyb, Small Mothers Against Decapentaplegic, and CCAAT/Enhancer-Binding Protein C/EBP Transcription Factors.

Authors:  Akanksha Sharma; Alok K Verma; Matthew Kofron; Ramesh Kudira; Alexander Miethke; Tong Wu; Jiang Wang; Chandrashekhar R Gandhi
Journal:  Hepatology       Date:  2020-10-22       Impact factor: 17.298

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.